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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
The primary objective of this review is to assess the effects, on mothers and families, of interventions (other than psychosocial, psycho-
logical and pharmacological) compared with usual care in postpartum depression.
Secondary objectives are to examine the effectiveness of:
1. specific types of physical therapies (e.g. bright light therapy, physical exercise, yoga, acupuncture, sleep deprivation);
2. specific types of nutraceuticals (e.g. omega-3 fatty acids);
3. specific types of herbal remedies (e.g. St. John's Wort).
Interventions (other than psychosocial, psychological and pharmacological) for treating postpartum depression (Protocol)









Cochrane Database of Systematic Reviews
B A C K G R O U N D
Description of the condition
Depression is common in the perinatal period and is linked to neg-
ative consequences for women and their families, including long-
term adverse outcomes in children (Stein 2014). In a landmark
meta-analysis of 59 studies, 13% of women were found to have ex-
perienced major depressive symptoms at some point during the
first 12 weeks following childbirth (number of women = 12,810)
(O'Hara 1996). A more recent systematic review found that the
period prevalence of major and minor depressive symptoms was
19.2% in the first 12 weeks postpartum, with a period prevalence
of 7.1% for a major depressive disorder (Gaynes 2005). Depression
appears to be more common in low- and middle-income countries
than in high-income countries, with reported rates of up to 20% in
postpartum women (Fisher 2012). Approximately 26.5% of women
with postpartum depression report episode onset before pregnan-
cy (Wisner 2013), which highlights preconception care as an impor-
tant management strategy.
Common symptoms of postpartum depression include emotion-
al lability (exaggerated changes in mood or affect in quick succes-
sion), dysphoria (unease or dissatisfaction), confusion, insomnia,
and guilt. Anxiety is also a frequent symptom; meta-analytic data
suggest that within the first six months postpartum, the prevalence
of coexisting anxiety and depressive symptoms is 8.2% (15 studies;
number of women = 14,731) (Falah-Hassani 2017). The course of
postpartum depression is variable and depends on a multitude of
factors, including: a woman’s prior depressive history, the persis-
tence versus resolution of stressors contributing to the depressive
episode, the severity of symptoms, and whether a woman seeks
appropriate treatment. While some postpartum depression will re-
solve spontaneously within a few weeks, approximately 20% of
episodes persist beyond the first year, and up to 40% of women will
experience a relapse of their depression (Goodman 2004).
Description of the intervention
Recommended treatment for postpartum depression depends on
factors related to a woman’s specific presentation, including sever-
ity of the current depressive episode, risk assessment, comorbidi-
ties, psychiatric history (e.g. severity of prior depressive episodes),
social stressors, social supports, and patient preference. Stepped-
care approaches, in which treatment options escalate in intensity
based on symptom severity and patient response, can be imple-
mented collaboratively.
The most commonly used treatments for depression are antide-
pressants, psychotherapy, or a combination of the two. While both
treatment strategies (alone and in combination) have been shown
to be effective, more recent meta-analyses have found high rates
of dropout and low rates of remission (Haller 2019). While pharma-
cotherapy is a frequent treatment choice for moderate to severe
depression, postpartum women are often hesitant to take antide-
pressants due to concerns about transmission to the infant through
breast milk (Dennis 2006). A Cochrane Review evaluated psycholog-
ical therapies (such as cognitive-behavioural therapy and interper-
sonal psychotherapy), as well as psychosocial interventions (e.g.
non-directive counselling, nurse/midwife home visits, peer sup-
port), for the treatment of postpartum depression (Dennis 2007).
The review found that both psychological and psychosocial inter-
ventions were effective in reducing depressive symptomatology.
Recent treatment guidelines — including those from the National
Institute for Health and Care Excellence (NICE, UK), the Canadian
Network for Mood and Anxiety Treatments (CANMAT, Canada), and
Beyond Blue (Australia) — support the importance of these inter-
ventions (Austin 2011; McQueen 2016; NICE 2014).
There are, however, a number of reasons why psychological ther-
apy and psychosocial interventions may not be an option. Psycho-
logical therapy may not be effective on its own for treating severe
depression. It can also be difficult for a new mother to attend psy-
chological therapy or a psychosocial programme, due to time con-
straints and the need to organise childcare. Furthermore, some
women — including those living in rural or remote areas —  may
have limited access to treatment due to a lack of transportation,
geographical distance, or the unavailability of a trained provider.
Interventions other than those which are pharmacological, psy-
chosocial or psychological are also available for treating depres-
sion. These "alternative" treatments, which include mind and phys-
ical body therapies and herbal remedies, are often considered be-
cause of the prevalent belief that "natural is better" (Ravindran
2009).
How the intervention might work
There are several alternative treatment options available for de-
pression. These include mind and physical body practices (e.g.
bright light therapy, physical exercise, yoga, acupuncture, sleep de-
privation, repetitive transcranial magnetic stimulation, transcra-
nial direct current stimulation), nutraceuticals (e.g. omega-3 fatty
acids), and herbal remedies (e.g. St. John's Wort).
Mind and physical body practices
Bright light therapy typically consists of exposure to a 10,000 lux
(intensity) fluorescent light box for 30 minutes per day, often in
the early morning at home. Response usually occurs within three
weeks. The mechanism of action, though still unclear, is thought
to be through correcting disturbed circadian rhythms and improv-
ing the regulation of chemical and neurotransmitter pathways (e.g.
serotonin and catecholamine systems) (Crowley 2012; Sohn 2005).
Another treatment option is physical exercise, where programmes
are usually delivered over eight to 20 weeks (average: 12 weeks),
three times per week for 30 to 60 minutes per session. The mecha-
nisms explaining the impact of various forms of physical exercise
on depression are not well understood. However, it is hypothesized
that the effect is explained by both psychological and neurobiolog-
ical factors. Psychological factors include increased sense of self-
efficacy and mastery as well as distraction from stress. Exercise is
also thought to impact complex biological and neural pathways
(Strohle 2009).
Yoga is a physical therapy which integrates body postures, medita-
tion, and breath control. It is typically practiced over four to eight
weeks, usually four times a week, for 45 to 60 minutes per session
(Ravindran 2009).
In acupuncture, special needles are used to pierce the skin surface
at specific points on the body to produce particular therapeutic
effects. Treatment usually lasts four to eight weeks; there is wide
variation in the number of needles (two to 16) and sessions used.
It is believed that acupuncture stimulates nerve fibres which then
trigger the central immune system and induce the release of neu-
Interventions (other than psychosocial, psychological and pharmacological) for treating postpartum depression (Protocol)









Cochrane Database of Systematic Reviews
rotransmitters (e.g. serotonin, norepinephrine, dopamine, and en-
dorphins) (Wang 2008).
Sleep deprivation involves keeping patients awake for long (40-
hour) or short (three- to four-hour) periods of time. One to six cycles
are usually used over four weeks (Ravindran 2009). Sleep depriva-
tion is thought to impact on depression through complex biologi-
cal processes such as the hypothalamic-pituitary adrenal axis, or
circadian rhythms (Ravindran 2009).
Emerging non-invasive, localized brain-stimulation therapies for
depression, that pose no theoretical risk to a developing fetus, are
increasingly being investigated for use in the perinatal population.
These include repetitive transcranial magnetic stimulation (rTMS),
which uses magnetic coils (typically targeted at the dorsolateral
prefrontal cortex) to modulate activity (Downar 2013), and tran-
scranial direct current stimulation (tDCS), which uses low-intensity
direct current via electrodes placed to modulate regional brain ac-
tivity in the prefrontal cortex (Vigod (in press)).
Nutraceuticals
Nutraceuticals are non-prescription natural health products. They
typically take the form of concentrated, naturally occurring sub-
stances such as vitamins and minerals (e.g. omega-3 fatty acids,
S-Adenosylmethionine (SAM-e), tryptophan, inositol, folic acid,
amino acids, alpha-lactabumin, dehydroepiandrosterone (DHEA),
and acetyl-L-carnitine) (Ravindran 2009). These are used alone
or in combination to promote general well-being. Omega-3 fat-
ty acids, for example, are polyunsaturated fatty acids found in
multiple biological systems. They have been studied in different
doses and formulations (e.g. cetyl esters of eicosapentanoic acid
(EPA) or docosahexaenoic acid (DHA), or a combination of both).
Omega-3 fatty acids are thought to be associated with processes
such as increased serotonergic neurotransmission, regulation of
corticotropin-releasing factor, and alterations in dopamine func-
tion (Freeman 2006); however, their mechanisms are not fully un-
derstood (Freeman 2011). Folate, which is involved in complex
pathways that comprise the one-carbon cycle, is thought to im-
pact depression by affecting synthesis of neurotransmitters such as
serotonin, dopamine, and norepinephrine (Freeman 2010).
Herbal remedies
Another sub-category of natural health products, herbal remedies
are derived from plants and plant extracts such as flowers, leaves,
roots, bark and berries. Herbal remedies are sold as non-prescrip-
tion products (Ravindran 2009). Examples are St. John's wort (Hy-
pericum perforatum), Gingko biloba, Crocus sativus, Lavandula an-
gustifolia, and Rhodiola rosea, to name a few. The mechanism of
action for herbal remedies is poorly understood. For example, St.
John's wort, one of the most common herbal remedies for depres-
sion, may operate through several pathways. There is some evi-
dence to suggest that it may inhibit uptake of serotonin, norepi-
nephrine, and dopamine. Other evidence suggests a role for regu-
lation of genes that control the hypothalamic-pituitary-adrenal ax-
is (Butterweck 2003).
Why it is important to do this review
Postpartum depression occurs during a period when the infant is
highly dependent on parental care and is very sensitive to the quali-
ty of the interaction. Concern for child development is warranted as
postpartum depression can interfere with good parenting interac-
tions and can cause substantial stress for children. The ever-grow-
ing literature clearly suggests that maternal depression adverse-
ly affects infant development (Stein 2014). In observational stud-
ies, infants of depressed mothers, compared with those of non-de-
pressed mothers, have been shown to be more fussy, score more
poorly on measures of intellectual and motor development, have
less secure attachments to their mothers and more difficult tem-
peraments, show delayed development of self-regulatory strate-
gies, react more negatively to stress, and exhibit poorer academ-
ic performance, lower levels of self-esteem, fewer social compe-
tencies, and higher levels of behavioural problems (England 2009;
Goodman 1999). A meta-analysis of 193 studies reported that ma-
ternal depression (not restricted to the postpartum period) was as-
sociated with higher levels of general psychopathology, internal-
ising behaviour, externalising behaviour, and lower levels of posi-
tive affect in the child (Goodman 2011). Of particular importance
is the observation that these effects were stronger if exposure to
maternal depression occurred when the child was at an early age.
There are several possible mechanisms by which maternal inter-
actions may transmit risk from the depressed mother to the child;
these include maternal modelling of depressed affect, behaviours,
and cognitions; inconsistent discipline practices; reduced positive
reinforcement for the child; and the development of an insecure
child attachment. Maternal depression may also have an indirect
effect through its detrimental impact on the marital relationship
and family functioning. International experts have clearly identi-
fied maternal depression as a major adversity for children and ef-
fective interventions to address this condition are one of the most
important public health strategies to reduce the long-term adverse
developmental effects on children. This Cochrane Review will pro-
vide evidence of the effectiveness of currently available alternative
treatments for postpartum depression and may provide a rationale
for the development of new and innovative treatments. As such, it
will aid in the prevention of poor child developmental outcomes.
In addition, a survey of primary care patients showed that, among
people with depression and anxiety, approximately the same pro-
portion (11%) report using complementary or alternative medicine
therapy (Roy-Byrne 2005), as those who use anti-depressant med-
ication (Mojtabai 2008). While this is an older survey, it does suggest
individuals are using alternative therapies at an increasing rate,
and so information about their effectiveness for the treatment of
postpartum depression is needed.
Three existing Cochrane Reviews are important to note in this con-
text. One of these evaluated the effect of psychosocial and psycho-
logical interventions for the treatment of postpartum depression
(Dennis 2007). In an analysis of ten trials, the authors found that
any psychosocial or psychological intervention, compared to usu-
al postpartum care, was associated with a reduction in the risk of
continued postpartum depression. This reduction was maintained
at the final assessment within the first year postpartum. The effect
was consistent across type of intervention (psychosocial or psy-
chological) and type of diagnosis at entry into the trial (clinical or
self-report of depressive symptomatology). The second review as-
sessed the effectiveness of antidepressants for treating postpar-
tum depression (Molyneaux 2014). The authors included six tri-
als: four evaluated the effectiveness of selective serotonin reup-
take inhibitors (SSRIs) relative to placebo, one compared sertra-
line and nortriptyline, and one compared any antidepressant to
treatment as usual. The authors found that SSRIs were significant-
ly more effective than placebo for treating women with postpar-
tum depression. However, the authors were unable to determine
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whether some antidepressants were more effective than others.
The third review, Dennis 2008, evaluated the effect of oestrogens
and progestins in preventing and treating postpartum depression.
Only two trials met the study inclusion criteria. The one treatment
trial suggested oestrogen may be effective in reducing depression
scores among women who had severe depression. There is current-
ly a gap in the evidence regarding the effect of other interventions
(e.g. physical therapies, nutraceuticals, and herbal remedies) in the
treatment of postpartum depression. This review will aim to syn-
thesize the available evidence on these interventions, and identify
areas for research
O B J E C T I V E S
The primary objective of this review is to assess the effects, on
mothers and families, of interventions (other than psychosocial,
psychological and pharmacological) compared with usual care in
postpartum depression.
Secondary objectives are to examine the effectiveness of:
1. specific types of physical therapies (e.g. bright light therapy,
physical exercise, yoga, acupuncture, sleep deprivation);
2. specific types of nutraceuticals (e.g. omega-3 fatty acids);
3. specific types of herbal remedies (e.g. St. John's Wort).
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include all published, unpublished and ongoing random-
ized controlled, cluster-randomized controlled, and cross-over tri-
als of interventions (other than psychosocial, psychological and
pharmacological) in which the primary or secondary aim is the re-
duction in postpartum depression. We will exclude quasi-random-
ized trials (e.g. those randomized by delivery date, or odd versus
even medical record numbers) from the analysis.
Types of participants
The study participants will include women of all ages who devel-
oped depression up to 12 months postpartum, who were identified
with either:
1. depressive symptomatology using cut-off scores on self-report
measures, e.g. the Edinburgh Postnatal Depression Scale (EPDS)
(Cox 1987), the Beck Depression Inventory (BDI) (Beck 1961); or
2. clinical depression using a diagnostic interview, e.g. Structured
Clinical Interview for DSM-IV (SCID) (Spitzer 1992).
We will accept all comorbidities, including mental and physical
conditions, as long as depression was the main focus of the trial.
We will include studies in which participants were recruited from
diverse settings, including hospital clinics, primary care, and in-
home. Where studies used self-report measures of depression, we
will use the threshold scores for the respective scales as applied by




1. Mind and physical body practices (e.g. bright light therapy, phys-
ical exercise, yoga, acupuncture, sleep deprivation);
2. Nutraceuticals (e.g. omega-3 fatty acids);
3. Herbal remedies (e.g. St. John's Wort).
We will include interventions that can be delivered on an individ-
ual or group basis during the postpartum period, either in-home,
during clinic visits, or by telephone (e.g. for physical exercise in-
terventions), by either a healthcare professional (e.g. nurse, mid-
wife, childbirth educator, physician, psychiatrist, psychologist) or
lay person (e.g. a specially trained person from the community, stu-
dent, research assistant). Studies will only be eligible for inclusion
if treatment was initiated postpartum. We will exclude studies in
which treatment started during pregnancy, even if postpartum de-
pression outcomes were reported. Interventions can range in fre-
quency, duration, and dosage. Interventions other than the ones
listed here as examples will be eligible for inclusion provided they
cannot be more reasonably characterized as psychosocial, psycho-
logical, or pharmacological.
Comparator interventions
Standard or usual care: this includes any appropriate healthcare
received during the course of the trial, including pharmacothera-
py (e.g. antidepressants), as deemed necessary by the clinician. We
will exclude trials which evaluate one treatment against another
treatment.
Types of outcome measures
Studies that meet the above criteria will be included regardless of
whether they report on the following outcomes.
Primary outcomes
1. Postpartum depression (as variously defined and measured by
trialists, including above a self-reported cut-off or a clinical di-
agnosis (dichotomous) and depression severity (continuous))
2. Adverse events or outcomes (variously defined, dichotomous)
a. For the mother (e.g., nausea, diarrhoea, headaches)




1. Maternal-infant attachment (e.g. Strange Situation (Ainsworth
1978), dichotomous or continuous)
2. Anxiety (e.g. State-Trait Anxiety Inventory (Spielberger 1970), di-
chotomous or continuous)
3. Maternal stress (e.g. Perceived Stress Scale (Cohen 1983), di-
chotomous or continuous)
4. Parenting stress (e.g. Parenting Stress Index (Abidin 1983), di-
chotomous or continuous)
5. Maternal perceived social support (e.g. Social Provisions Scale
(Cutrona 1987), dichotomous or continuous)
6. Maternal dissatisfaction with intervention (variously defined, di-
chotomous or continuous)
Infant
1. Infant developmental assessments (e.g. Ages and Stages Ques-
tionnaire (Squires 1999), dichotomous or continuous)
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Family
1. Marital discord (e.g. Dyadic Adjustment Scale (Spanier 1976), di-
chotomous or continuous)
Timing of outcome assessment
For all comparisons, we will classify outcomes as (1) assessment
carried out immediately post-treatment, and (2) final assessment
carried out within the first year postpartum. Our primary time point
will be the assessment carried out immediately post-treatment. If
the study includes multiple assessments from the post-treatment
period up to one year postpartum, we will include the last follow-up
assessment.
Hierarchy of outcome measures
Where studies include multiple measures of the same outcome, we
will include in data analysis the most commonly used measure.
For example, for self-reported measures of postpartum depression
(e.g. the Edinburgh Postnatal Depression Scale (EPDS) (Cox 1987)
and Hamilton Rating Scale for Depression (HRSD) (Hamilton 1960)),
we will use the EPDS. Where the authors include both clinician-ad-
ministered scales and self-report measures, we will include in data
analysis the clinician-administered scale.
Search methods for identification of studies
Cochrane Common Mental Disorders Controlled Trials Register
(CCMDCTR)
The Cochrane Common Mental Disorders Group (CCMD) maintains
two archived clinical trials registers at its editorial base in York,
UK: a references register and a studies-based register. The CCMD-
CTR-References Register contains over 40,000 reports of random-
ized controlled trials (RCTs) in depression, anxiety and neurosis. Ap-
proximately 50% of these references have been tagged to individ-
ual, coded trials. The coded trials are held in the CCMDCTR-Studies
Register and records are linked between the two registers through
the use of unique Study ID tags. Coding of trials is based on the
EU-Psi coding manual, using a controlled vocabulary; (please con-
tact the CCMD Information Specialists for further details). Reports
of trials for inclusion in the Group's registers are collated from rou-
tine (weekly), generic searches of MEDLINE (1950 to 2016), Embase
(1974 to 2016) and PsycINFO (1967 to 2016); quarterly searches of
the Cochrane Central Register of Controlled Trials (CENTRAL) and
review-specific searches of additional databases. Reports of trials
are also sourced from international trial registers via the World
Health Organization's trials portal (the International Clinical Trials
Registry Platform (ICTRP)), pharmaceutical companies, the hand-
searching of key journals, conference proceedings and other (non-
Cochrane) systematic reviews and meta-analyses.
Further details of CCMD's core search strategies (used to identify
RCTs for their specialized register) can be found on the Group's web-
site, for transparency they are also summarized in Appendix 1. The
CCMDCTR is current to June 2016.
Electronic searches
1. Cochrane Specialized Registers
Common Mental Disorders Group
The CCMDCTR will be searched using the following strategies.
CCMDCTR-Studies
(Diagnosis = "Depression, Postpartum") or (Diagnosis = Depress*
and Comorbid Diagnosis= Pregnan*)
CCMDCTR-References will be searched using a more sensitive set
of terms to identify additional reports of RCTs not yet tagged to in-
dividual studies:
((depress* NEAR (postpartum* or post-partum* or "post partum"
or postnatal* or post-natal* or "post natal" or puerp* or perinatal*
or peri-natal* or "peri natal*" or peripartum* or peri-partum* or
"peri partum*" or pregnan* or maternal*)) or (baby-blue* or "baby
blue*")):ti,ab,ky,kw,emt,mh
Cochrane Pregnancy and Childbirth Group
A search of the Cochrane Pregnancy and Childbirth Group (PCG) Tri-
als Register will also be conducted. This register also contains rele-
vant RCTs from MEDLINE, Embase, PsycINFO and CENTRAL (further
details available on the PCG website).
There will be no restrictions on date, language or publication status
applied to the searches.
2. International Trial Registries
International trial registries will be searched via the World Health
Organization's trials portal (ICTRP) and ClinicalTrials.gov to identi-
fy unpublished or ongoing studies.
3. Biomedical Databases
Additional searches will be conducted on Ovid MEDLINE, PsycINFO
and the Cochrane Library (2016 onwards) to cover the period when
the CCMDCTR fell out of date with the editorial group’s move from




For references lists, we will conduct forward and backward citation
tracking of all included studies to identify additional studies missed
from the original electronic searches (e.g. unpublished or in-press
citations). We will not apply any language restrictions.
Correspondence
We will make contact with experts in the field to request additional
trial data or information on unpublished or ongoing studies.
Data collection and analysis
Selection of studies
Two review authors (JVEB and HKB) will independently assess for
inclusion all the potential studies we identified as a result of the
search strategy. After assessing titles and abstracts, we will retrieve
full-text articles for potentially eligible studies. We will then include
and exclude studies according to the methods described above. We
will resolve any uncertainties regarding the appropriateness for in-
clusion through discussion or consultation with a third review au-
thor (CLD). We will exclude duplicate studies and record reasons for
exclusion or ineligible studies (outlined in the 'Characteristics of ex-
cluded studies' table). We will collate multiple reports related to the
same study so that each study rather than each report will be the
unit of interest in the review. We will record the selection process
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in sufficient detail to complete a PRISMA flow diagram and 'Char-
acteristics of included studies' table.
Data extraction and management
We will use a previously designed data extraction form to collect
study characteristics related to trial methods (method of allocation
generation, method of allocation concealment, loss of participants
to follow-up, blinding, use of intention-to-treat analysis), inclusion
and exclusion criteria for participants, details of the intervention
and control groups, as well as outcome data (number of events and
total number of participants or means and standard deviations for
intervention and control groups, as relevant). For eligible studies,
two review authors will independently extract the data using the
agreed form. We will resolve discrepancies through discussion or,
if required, we will consult a third person. We will enter data into
Review Manager 5 software or RevMan Web (Review Manager 2014;
RevMan Web 2019), and check for accuracy by comparing the data
presented in the systematic review with the study reports. When
information regarding any of the above is unclear, we will attempt
to contact authors of the original reports to provide further details.
Main planned comparisons
We will make the following treatment comparisons.
1. All physical therapies versus standard care or usual care
2. All nutraceuticals versus standard care or usual care
3. All herbal remedies versus standard care or usual care
Data permitting, we will conduct subgroup analyses by individual
treatment type.
Assessment of risk of bias in included studies
Two review authors will independently assess risk of bias for each
study using the criteria outlined in the Cochrane Handbook for Sys-
tematic Reviews of Interventions (Higgins 2011). We will resolve any
disagreements by discussion or by involving another author. For
the following domains, we will judge each study to be at "high",
"low", or "unclear" risk of bias, using quotes from the trial publica-
tion to support our assessment.
1. Sequence generation (checking for possible selection bias)
2. Allocation concealment (checking for possible selection bias)
3. Blinding of participants and personnel (checking for possible
performance bias)
4. Blinding of outcome assessors (checking for possible detection
bias)
5. Incomplete outcome data (checking for possible attrition bias
through withdrawals, dropouts, protocol deviations)
6. Selective reporting bias
7. Other sources of bias
For cluster-randomized trials, we will describe the following (in
accordance with the Cochrane Handbook, section 16.3.2 Higgins
2011).
1. Recruitment bias: whether the individuals participating in the
trial were blinded to the type of cluster they were in before
agreeing to participate
2. Baseline imbalances: whether there were differences in baseline
characteristics between the randomized groups
3. Loss of clusters: whether any complete clusters were lost to fol-
low-up and the reasons
4. Incorrect analysis: whether the proper statistical analysis was
carried out for a cluster-randomized design
5. Differences in intervention effects: whether the cluster random-
ization method could have resulted in different intervention ef-
fects than an individually-randomized trial
With reference to (1) to (6) above, we will assess the likely magni-
tude and direction of the bias and whether we consider it to be like-
ly to impact on the findings. We will explore the impact of the lev-
el of bias through undertaking sensitivity analyses; see Sensitivity
analysis.
Measures of treatment effect
Dichotomous data
For dichotomous data, we will present results as summary risk ratio
(RR) with 95% confidence intervals (CIs).
Continuous data
For continuous data, we will use the mean difference if outcomes
were measured in the same way between trials. We will use the
standardized mean difference (SMD) to combine trials that exam-
ined the same outcome, but used different measures.
Unit of analysis issues
Cluster-randomized studies
We will include cluster-randomized trials in the analyses along with
individually-randomized trials. We will adjust the sample sizes us-
ing the methods described in section 16.3.4 of the Cochrane Hand-
book, using an estimate of the intracluster correlation coefficient
(ICC) derived from the trial. If there is little heterogeneity between
the study designs, we will synthesize the relevant information from
the cluster-randomized trials and individually-randomized trials
we identify.
We will also acknowledge heterogeneity in the randomization unit
and will perform a sensitivity analysis to investigate the effects of
the randomization unit.
Studies with multiple treatment groups
We will include studies with multiple treatment arms. We will de-
scribe all treatment arms in the 'Characteristics of studies' tables.
For the meta-analysis, we will combine groups to conduct a single
pair-wise comparison, where possible. We will also combine con-
trol arms if there is more than one that meets criteria for ‘standard
care’.
Dealing with missing data
For included studies, we will contact study authors for missing da-
ta. We will note levels of attrition. We will explore the impact of in-
cluding studies with high levels of missing data in the overall as-
sessment of treatment effect by using sensitivity analysis. We will
compare those trials where 80% of data on a given outcome were
available for those who were originally randomized versus those
with less than 80%. For all outcomes, we will carry out analyses, as
far as possible, on an intention-to-treat basis, i.e. we will attempt
to include all participants randomized to each group in the analy-
ses, and all participants will be analyzed in the group to which they
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were allocated, regardless of whether or not they received the al-
located intervention. The denominator for each outcome in each
trial will be the number randomized minus any participants whose
outcomes are known to be missing. It is important to note that if
data remain missing after attempts to obtain them, for some mea-
sures of variation where there is an approximate or direct algebraic
relationship with the standard deviation, it may be possible to ob-
tain the required statistic even if it is not published in the paper, as
explained in the Cochrane Handbook, sections 7.7.3.2 to 7.7.3.7. We
will closely examine our missing data and determine if imputations
are possible.
Assessment of heterogeneity
We will assess statistical heterogeneity visually by studying the de-
gree of overlap of the CIs for individual studies in a forest plot. We
will also carry out more formal assessments using the t2, I2 and Chi2
statistics. We will regard heterogeneity as substantial if t2 is greater
than zero or if there is a low P value (less than 0.10) in the Chi2 test
for heterogeneity. We will interpret the I2 value in accordance with
the Cochrane Handbook (Higgins 2011), as follows:
1. 0% to 40%: might not be important;
2. 30% to 60%: may represent moderate heterogeneity;
3. 50% to 90%: may represent substantial heterogeneity;
4. 75% to 100%: considerable heterogeneity.
Assessment of reporting biases
For the primary outcome (postpartum depression), if there are 10 or
more studies in the meta-analysis, we will investigate possible re-
porting biases (such as publication bias) using funnel plots. We will
assess funnel plots visually, and if there is any obvious asymmetry
apparent (often attributed to publication bias) we will seek statis-
tical advice on carrying out formal tests for funnel plot asymmetry.
Data synthesis
We will carry out statistical analysis using Review Manager 5 soft-
ware (Review Manager 2014). We will use fixed-effect meta-analysis
for combining data where it is reasonable to assume that the stud-
ies are estimating the same underlying treatment effect, i.e. where
trials examine similar interventions, and the trials' populations and
methods are judged to be sufficiently similar. If there is clinical het-
erogeneity sufficient to expect that the underlying treatment ef-
fects differ between trials, or if substantial statistical heterogene-
ity is detected, we will use random-effects meta-analysis to pro-
duce an overall summary if an average treatment effect across trial
is considered clinically meaningful. The random-effects summary
will be treated as the average range of possible treatment effects
and we will consider the clinical implications of treatment effects
differing between trials. If the average treatment effect is not clin-
ically meaningful we will not combine trials. If we use random-ef-
fects analyses, the results will be presented as the average treat-
ment effect with its 95% confidence interval, and the estimates of
t2 and I2. We will not use the random-effects model as a primary
analysis if less than five studies are included in this review.
Subgroup analysis and investigation of heterogeneity
We plan to complete a priori subgroup analyses to investigate the
effect of:
1. type of specific physical therapy (e.g. bright light therapy, phys-
ical exercise, yoga, acupuncture, sleep deprivation);
2. type of nutraceuticals (e.g. omega-3 fatty acids);
3. type of herbal remedies (e.g. St. John's Wort).
4. intervention mode (e.g. individually-based physical therapy in-
terventions, group-based physical therapy interventions);
5. sample selection criteria (e.g. women selected based on clinical-
ly diagnosed depression versus self-reported depression).
Where data are available, we will conduct subgroup analyses for
our primary outcome:
Postpartum depression (as variously defined and measured by tri-
alists, including above a self-reported cut-off or a clinical diagnosis
(dichotomous) and depression severity (continuous))
For random-effects and fixed-effect meta-analyses, we will assess
differences between subgroups by inspection of the subgroups'
confidence intervals; non-overlapping confidence intervals sug-
gest a statistically significant difference in treatment effect be-
tween the subgroups. We will also carry out formal subgroup analy-
ses, available in Review Manager 5 (Review Manager 2014).
Sensitivity analysis
We plan to conduct sensitivity analyses, for the primary outcomes,
in instances in which there was a high risk of bias due to any of the
following:
1. inadequate allocation concealment;
2. unblinded outcome assessment or outcome assessment uncer-
tain;
3. incomplete outcome data (more than 20% missing data) for any
of the included trials.
These sensitivity analyses will involve removing studies with high
and unknown risk of bias and we will only undertake them where
there is an adequate number of studies.
Summary of findings
We will use the GRADE approach (Schunemann 2009) to evalu-
ate the quality of the available evidence. We will create 'Summary
of findings' tables using GRADEpro GDT software (GRADEPro GDT
2015). We will import data from Review Manager 5 into GRADEpro
GDT. Tables will then be generated that provide information about:
(1) the overall quality of the available evidence for each specific out-
come, (2) the magnitude of the effect of the intervention, and (3)
the sum of the available data on each outcome. We will assess the
quality of the available evidence based on the following five con-
siderations:
1. limitations in study design;
2. indirectness of evidence;
3. heterogeneity of results;
4. imprecision of effect estimates;
5. publication bias.
We will classify the quality of evidence for each outcome that in-
cludes pooled data as follows:
1. high quality (further research will not likely change our confi-
dence in the effect estimate);
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2. moderate quality (further research will likely impact our confi-
dence in the effect estimate);
3. low quality (further research will very likely impact our confi-
dence in the effect estimate);
4. very low quality (we are very uncertain about the effect esti-
mate).
We will downgrade the quality rating by one level for serious issues
and by two levels for very serious issues. Our 'Summary of findings'
tables will include the following outcomes, measured immediate-






5. maternal perceived social support.
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A P P E N D I C E S
Appendix 1. CCMDCTR core search strategies
The core search strategies used to identify reports of RCTs for the Cochrane Common Mental Disorders Specialised Register (CCMD-CTR),
are listed below.
OVID MEDLINE (1950 to date): 1. eating disorders/ or anorexia nervosa/ or binge-eating disorder/ or bulimia nervosa/ or female athlete tri-
ad syndrome/ or pica/ 2. hyperphagia/ or bulimia/ 3. self-injurious behavior/ or self mutilation/ or suicide/ or suicidal ideation/ or suicide,
attempted/ 4. mood disorders/ or affective disorders, psychotic/ or bipolar disorder/ or cyclothymic disorder/ or depressive disorder/ or
depression, postpartum/ or depressive disorder, major/ or depressive disorder, treatment-resistant/ or dysthymic disorder/ or seasonal
affective disorder/ 5. neurotic disorders/ 6. depression/ 7. adjustment disorders/ 8. exp antidepressive agents/ 9. anxiety disorders/ or
agoraphobia/ or neurocirculatory asthenia/ or obsessive-compulsive disorder/ or obsessive hoarding/ or panic disorder/ or phobic disor-
ders/ or stress disorders, traumatic/ or combat disorders/ or stress disorders, post-traumatic/ or stress disorders, traumatic, acute/ 10.
anxiety/ or anxiety, castration/ or koro/ 11. anxiety, separation/ 12. panic/ 13. exp anti-anxiety agents/ 14. somatoform disorders/ or body
dysmorphic disorders/ or conversion disorder/ or hypochondriasis/ or neurasthenia/ 15. hysteria/ 16. munchausen syndrome by proxy/
or munchausen syndrome/ 17. fatigue syndrome, chronic/ 18. obsessive behavior/ 19. compulsive behavior/ or behavior, addictive/ 20.
impulse control disorders/ or firesetting behavior/ or gambling/ or trichotillomania/ 21. stress, psychological/ or burnout, professional/
22. sexual dysfunctions, psychological/ or vaginismus/ 23. anhedonia/ 24. affective symptoms/ 25. *mental disorders/ 26. (eating disorder*
or anorexia nervosa or bulimi* or binge eat* or (self adj (injur* or mutilat*)) or suicide* or suicidal or parasuicid* or mood disorder* or
affective disorder* or bipolar i or bipolar ii or (bipolar and (affective or disorder*)) or mania or manic or cyclothymic* or depression or
depressive or dysthymi* or neurotic or neurosis or adjustment disorder* or antidepress* or anxiety disorder* or agoraphobia or obsess* or
compulsi* or panic or phobi* or ptsd or posttrauma* or post trauma* or combat or somatoform or somati#ation or medical* unexplained
or body dysmorphi* or conversion disorder or hypochondria* or neurastheni* or hysteria or munchausen or chronic fatigue* or gambling
or trichotillomania or vaginismus or anhedoni* or affective symptoms or mental disorder* or mental health).ti. 27. (or/1-26) 28. controlled
clinical trial.pt. 29. randomized controlled trial.pt. 30. (randomi#ed or randomi#ation).ab,ti. 31. randomly.ab. 32. (random* adj3 (admin-
ist* or allocat* or assign* or class* or control* or determine* or divide* or distribut* or expose* or fashion or number* or place* or recruit*
or subsitut* or treat*)).ab. 33. placebo*.ab,ti. 34. drug therapy.fs. 35. trial.ab,ti. 36. groups.ab. 37. (control* adj3 (trial* or study or stud-
ies)).ab,ti. 38. ((singl* or doubl* or tripl* or trebl*) adj3 (blind* or mask* or dummy*)).mp. 39. clinical trial, phase ii/ or clinical trial, phase
iii/ or clinical trial, phase iv/ or randomized controlled trial/ or pragmatic clinical trial/ 40. (quasi adj (experimental or random$)).ti,ab. 41.
((waitlist* or wait* list* or treatment as usual or tau) adj3 (control or group)).ab. 42. (or/28-41) 43. (27 and 42)
OVID EMBASE (1974 to date): 1. eating disorder/ or anorexia nervosa/ or binge eating disorder/ or bulimia/ or female athlete triad/ or food
aversion/ or pica/ 2. automutilation/ 3. suicidal behavior/ or self poisoning/ or suicidal ideation/ or suicide/ or suicide attempt/ 4. mania/
or hypomania/ or manic psychosis/ 5. bipolar disorder/ or bipolar depression/ or bipolar i disorder/ or bipolar ii disorder/ or bipolar mania/
or cyclothymia/ or manic depressive psychosis/ or "mixed mania and depression"/ or rapid cycling bipolar disorder/ 6. depression/ or agi-
tated depression/ or atypical depression/ or depressive psychosis/ or dysphoria/ or dysthymia/ or endogenous depression/ or involutional
depression/ or major depression/ or masked depression/ or melancholia/ or "mixed anxiety and depression"/ or "mixed depression and
dementia"/ or mourning syndrome/ or organic depression/ or postoperative depression/ or premenstrual dysphoric disorder/ or pseu-
dodementia/ or puerperal depression/ or reactive depression/ or recurrent brief depression/ or seasonal affective disorder/ 7. puerperal
psychosis/ 8. neurosis/ or affective neurosis/ or anxiety neurosis/ or dysthymia/ or hysteria/ or neurasthenia/ or psychasthenia/ 9. adjust-
ment disorder/ 10. anxiety/ 11. anxiety disorder/ or acute stress disorder/ or anxiety neurosis/ or cardiac anxiety/ or distress syndrome/ or
generalized anxiety disorder/ or koro/ or "mixed anxiety and depression"/ or panic/ or posttraumatic stress disorder/ or psychasthenia/ or
separation anxiety/ 12. obsessive compulsive disorder/ or compulsion/ or obsession/ 13. phobia/ or agoraphobia/ or claustrophobia/ or
homophobia/ or neophobia/ or social phobia/ 14. somatoform disorder/ or body dysmorphic disorder/ or cardiac anxiety/ or conversion
disorder/ or delusional pregnancy/ or hypochondriasis/ or masked depression/ or psychogenic pain/ or somatic delusion/ or somatiza-
tion/ 15. mood disorder/ or affective neurosis/ or affective psychosis/ or blunted affect/ or major affective disorder/ or minor affective dis-
order/ 16. munchausen syndrome by proxy/ or munchausen syndrome/ 17. psychosexual disorder/ or anorgasmia/ or castration anxiety/
or frigidity/ or koro/ or libido disorder/ or oedipus complex/ or orgasm disorder/ or psychogenic impotence/ or sexual addiction/ or sexual
arousal disorder/ or vaginism/ 18. impulse control disorder/ or intermittent explosive disorder/ or kleptomania/ or pathological gambling/
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or pyromania/ or trichotillomania/ 19. mental stress/ 20. emotional disorder/ 21. mood disorder/ or affective neurosis/ or blunted affect/
or depression/ or major affective disorder/ or mania/ or minor affective disorder/ 22. (or/1-21) 23. randomized controlled trial.de. 24. ran-
domization.de. 25. placebo.de. 26. placebo$.ti,ab. 27. randomi#ed.ti,ab. 28. randomly.ab. 29. ((singl$ or doubl$ or trebl$ or tripl$) adj3
(blind$ or mask$ or dummy)).mp. 30. factorial$.ti,ab. 31. allocat$.ti,ab. 32. assign$.ti,ab. 33. volunteer$.ti,ab. 34. crossover procedure.de.
35. (crossover$ or cross over$).ti,ab. 36. (quasi adj (experimental or random$)).mp. 37. (control$ adj3 (trial$ or study or studies or group
$)).ti,ab. 38. ((animal or nonhuman) not (human and (animal or nonhuman))).de. 39. (or/23-37) 40. (39 not 38) 41. (22 and 40)
OVID PsycINFO (1967 to date): 1. eating disorders/ or anorexia nervosa/ or bulimia/ or hyperphagia/ or kleine levin syndrome/ or pica/
or "purging (eating disorders)"/ 2. aphagia/ 3. coprophagia/ 4. binge eating/ 5. self destructive behavior/ or attempted suicide/ or head
banging/ or self inflicted wounds/ or self injurious behavior/ or self mutilation/ or suicide/ 6. suicide prevention/ 7. suicidal ideation/ 8.
affective disorders/ 9. affective psychosis/ 10. bipolar disorder/ or cyclothymic personality/ 11. major depression/ or anaclitic depression/
or dysthymic disorder/ or endogenous depression/ or postpartum depression/ or reactive depression/ or recurrent depression/ or treat-
ment resistant depression/ 12. atypical depression/ 13. "depression (emotion)"/ 14. seasonal affective disorder/ 15. anxiety disorders/ or
acute stress disorder/ or castration anxiety/ or death anxiety/ or generalized anxiety disorder/ or obsessive compulsive disorder/ or pan-
ic disorder/ or posttraumatic stress disorder/ or separation anxiety/ 16. phobias/ or acrophobia/ or agoraphobia/ or claustrophobia/ or
ophidiophobia/ or school phobia/ or social phobia/ 17. "debriefing (psychological)"/ 18. neurosis/ or childhood neurosis/ or experimental
neurosis/ or occupational neurosis/ or traumatic neurosis/ 19. adjustment disorders/ 20. coping behavior/ 21. adjustment/ or exp emo-
tional adjustment/ or occupational adjustment/ or school adjustment/ or social adjustment/ 22. emotional trauma/ 23. stress/ or chronic
stress/ or environmental stress/ or occupational stress/ or psychological stress/ or social stress/ or stress reactions/ 24. anxiety/ or com-
puter anxiety/ or mathematics anxiety/ or performance anxiety/ or social anxiety/ or speech anxiety/ or test anxiety/ 25. panic attack/
or panic/ or panic disorder/ 26. somatoform disorders/ or body dysmorphic disorder/ or hypochondriasis/ or neurasthenia/ or neuroder-
matitis/ or somatization disorder/ or somatoform pain disorder/ 27. conversion disorder/ or hysterical paralysis/ or hysterical vision dis-
turbances/ or pseudocyesis/ 28. somatization/ 29. hysteria/ or mass hysteria/ 30. hysterical paralysis/ 31. histrionic personality disorder/
32. malingering/ 33. factitious disorders/ or munchausen syndrome by proxy/ or munchausen syndrome/ 34. chronic fatigue syndrome/
35. compulsions/ or repetition compulsion/ 36. obsessions/ 37. obsessive compulsive personality disorder/ 38. trichotillomania/ 39. gam-
bling/ or pathological gambling/ 40. sexual function disturbances/ or dyspareunia/ or erectile dysfunction/ or female sexual dysfunction/
or inhibited sexual desire/ or premature ejaculation/ or vaginismus/ 41. premenstrual dysphoric disorder/ 42. *mental disorders/ 43. (eat-
ing disorder* or anorexi* or bulimi* or binge eat* or (self adj (injur* or mutilat*)) or suicide* or suicidal or parasuicid* or mood disorder*
or affective disorder* or bipolar i or bipolar ii or (bipolar and (affective or disorder*)) or mania or manic or cyclothymi* or depression or
depressive or dysthymi* or neurotic or neurosis or adjustment disorder* or antidepress* or anxiety disorder* or agoraphobia or obsess* or
compulsi* or panic or phobi* or ptsd or posttrauma* or post trauma* or combat or somatoform or somati#ation or medical* unexplained or
body dysmorphi* or conversion disorder or hypochondria* or neurastheni* or hysteria or munchausen or chronic fatigue* or gambling or
trichotillomania or vaginismus or anhedoni* or affective symptoms or mental disorder* or mental health).ti,id. 44. (or/1-43) 45. treatment
effectiveness evaluation.sh. 46. clinical trials.sh. 47. mental health program evaluation.sh. 48. placebo.sh. 49. placebo$.ti,ab. 50. random-
ly.ab. 51. randomi#ed.ti,ab. 52. trial$.ti,ab. 53. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$ or dummy)).mp. 54. (control$
adj3 (trial$ or study or studies or group$)).ti,ab. 55. "2000".md. 56. factorial$.ti,ab. 57. allocat$.ti,ab. 58. assign$.ti,ab. 59. volunteer$.ti,ab.
60. (crossover$ or cross over$).ti,ab. 61. (quasi adj (experimental or random$)).mp. 62. ((waitlist* or wait* list* or treatment as usual or tau)
adj3 (control or group)).ab. 63. (random* adj3 (administ* or class* or control* or determine* or divide* or distribut* or expose* or fashion
or number* or place* or recruit* or subsitut* or treat*)).ab. 64. (or/45-63) 65. (44 and 64)
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